Trials / Active Not Recruiting
Active Not RecruitingNCT05779592
A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma
An Observational Study Evaluating Treatment Situations of Adjuvant Nivolumab for Muscle-invasive Urothelial Carcinoma in Japan
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness, safety, and actual treatment status of nivolumab administered as an adjuvant treatment for participants with muscle-invasive urothelial carcinoma (MIUC), including bladder, renal pelvis, and ureteral cancer, in a Japanese real-world clinical practice.
Conditions
Timeline
- Start date
- 2022-11-23
- Primary completion
- 2027-03-31
- Completion
- 2027-09-30
- First posted
- 2023-03-22
- Last updated
- 2025-06-27
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05779592. Inclusion in this directory is not an endorsement.